MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1136/rmdopen-2025-006356

Медицинская библиотека · RMD open · 2026

Characteristics, treatments and outcomes of patients with dermatomyositis using real-world data.

George Michael, Romich Ellen, Riley Thomas R, England Bryant R, Daigle Shanette, Holladay Emily E, Su Yujie, Xie Fenglong, Masri Karim R, Curtis Jeffrey R

СтатьяПеревод в очереди

Аннотация

OBJECTIVE

Studies of dermatomyositis (DM) are frequently limited to single-centre cohorts. We used two large nationally representative US cohorts to conduct a descriptive epidemiological study of the characteristics, treatments and outcomes of patients with incident DM.

METHODS

This retrospective study identified two DM inception cohorts using (1) commercial claims and (2) electronic health record (EHR) data from the Excellence Network in Rheumatology to Innovate Care and High-impact research (ENRICH), a community rheumatology practice-based research network. Patient characteristics, treatments and healthcare utilisation were assessed using the 18 months before and 12 months after diagnosis in claims and the 12 months before and after diagnosis in EHR data.

RESULTS

We identified 2475 patients (claims) and 1196 patients (EHR) with incident DM. Among 998 patients in the EHR cohort with available laboratory data, 472 had available myositis panel results, with 165 (35.0%) having a positive myositis-specific antibody. Glucocorticoid use was common, 68.7% and 73.8% in the two cohorts, respectively, with initial doses most often >20 mg/day; among glucocorticoid users, mean cumulative dose was 1407 mg in the claims cohort. Hydroxychloroquine, methotrexate and mycophenolate were the most commonly used immunomodulatory therapies. During follow-up in the claims data cohort, incidence per 1000 person-years was 92.2, 15.3, 6.4, 2.9 and 2.1 for all-cause hospitalisation, malignancy, interstitial lung disease, gastrostomy tube placement and myocarditis, respectively.

CONCLUSION

Administrative claims and EHR data can be leveraged to assess treatment patterns and longitudinal outcomes/disease manifestations in incident dermatomyositis cohorts. This study highlights a high burden of glucocorticoid exposure, significant heterogeneity in treatment and high healthcare utilisation in this population.

Для цитирования: George Michael, Romich Ellen, Riley Thomas R, England Bryant R, Daigle Shanette, Holladay Emily E, Su Yujie, Xie Fenglong, Masri Karim R, Curtis Jeffrey R. Characteristics, treatments and outcomes of patients with dermatomyositis using real-world data.. RMD open. 2026. DOI: 10.1136/rmdopen-2025-006356.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.